This Article


Creative Commons License
Except where otherwise noted, this work is licensed under Creative Commons Attribution-NonCommercial 4.0 International License.

Future Outcome of Sonography BI-RADS Category 3 Lesions

1 Tehran University of Medical Sciences, Tehran, Iran
*Corresponding author: Afsaneh Alikhassi, Tehran University of Medical Sciences, Tehran, Iran, E-mail:
Iranian Journal of Radiology. 2017 May; Special iss(5): e47968 , DOI: 10.5812/iranjradiol.47968
Article Type: Abstract; Received: Dec 21, 2016; Accepted: Feb 8, 2017; epub: Apr 13, 2017; ppub: May 2017


Objectives: This study aims to find the frequency and the malignancy rate of BI-RADS category 3 lesions detected on screening breast ultrasound and to evaluate whether they fullfilled the requirements of the latest American college of radiology imaging and reporting system.

Methods: Of 500 asymptomatic women who came to our center for screening sonography themselves or referred by their clinician, patients for whom BI-RADS category 3 lesions were seen on the ultrasound were selected. Clinical outcome of these lesions using one year follow up, biopsy or a combination of both were evaluated.

Results: The frequency of BI-RADS category 3 lesions detected on screening ultrasound was 18% (90/500). Of these patients, one was eventually proven to have malignancy with malignancy rate of 1.1%. This detected malignancy was early breast cancer with no lymph node metastasis.

Conclusions: Although the frequency of ultrasound BI-RADS category 3 lesions is considerably high (18 %), the malignancy rate is low (1.1%). Therefore careful assessment and follow up of BI-RADS category 3 can avoid unnecessary biopsy or surgery.

This is an abstract presented in the 33rd Iranian congress of radiology (ICR) and the 15th congress of Iranian radiographic science association (IRSA)